-
-
-
-
-
-
-
ImmunityBio presents bladder cancer treatment comparison data at AUA
-
-
-
-
-
-
-
ImmunityBio responds to FDA concerns over promotional materials
-
-
-
-
-
-
-
ImmunityBio receives approval for ANKTIVA in Macau for bladder cancer
-
-
-
-
-
-
-
ImmunityBio (IBRX) January 5.5 puts active as share price down 14.5%
-
-
-
-
-
-
-
ImmunityBio wins European approval for bladder cancer treatment
-
-
-
-
-
-
-
Increasing unusual option volume: IRE IBRX QNCX FE IREX RVMD RPD
-
-
-
-
-
-
-
ImmunityBio amends stock sale agreement to authorize $460M offering
-
416,803 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

